Product Overview
Semimox-625 represents a significant advancement in antibiotic therapy, combining the broad-spectrum efficacy of Amoxicillin with the beta-lactamase inhibiting properties of Clavulanic Acid. This synergistic combination ensures therapeutic success against a wide range of bacterial pathogens, including those resistant to conventional penicillins.
Mechanism of Action:
- Amoxicillin: Bactericidal beta-lactam antibiotic that inhibits bacterial cell wall synthesis
- Clavulanic Acid: Beta-lactamase inhibitor that protects amoxicillin from enzymatic degradation
- Synergistic Effect: Combined action extends spectrum to include beta-lactamase producing organisms
Clinical Advantages:
The combination provides superior bacterial eradication rates compared to amoxicillin alone, particularly in infections caused by resistant organisms. The formulation ensures optimal tissue penetration and sustained therapeutic levels.
Important: This is a prescription-only medication. Use only under medical supervision and complete the full course as prescribed.
Dosage & Administration
Adult Dosage:
- Standard Infections: 1 tablet every 12 hours (twice daily)
- Severe Infections: 1 tablet every 8 hours (three times daily)
- Duration: 7-14 days depending on infection severity
- Administration: Take at the start of a meal to enhance absorption and reduce GI side effects
Pediatric Dosage:
- Children >40kg: Same as adult dose
- Children <40kg: Dosing based on body weight (consult pediatrician)
- Infants <3 months: Not recommended
Special Populations:
- Elderly: No dose adjustment usually required
- Renal Impairment: Dose reduction required (creatinine clearance <30 mL/min)
- Hepatic Impairment: Use with caution, monitor liver function
- Pregnancy: Category B - Use only if clearly needed
- Nursing Mothers: Excreted in breast milk - use with caution
Important Guidelines:
- Complete the full prescribed course even if symptoms improve
- Take at regular intervals to maintain therapeutic levels
- Do not skip doses or stop treatment early
- Store in cool, dry place away from children
Indications & Uses
Primary Indications:
- Respiratory Tract Infections: Acute bacterial sinusitis, community-acquired pneumonia, acute exacerbation of chronic bronchitis
- Urinary Tract Infections: Cystitis, pyelonephritis, complicated UTIs
- Skin & Soft Tissue Infections: Cellulitis, abscesses, wound infections
- Dental Infections: Periodontitis, dental abscesses
- Otitis Media: Acute middle ear infections
- Gynecological Infections: Pelvic inflammatory disease, endometritis
Bacterial Coverage:
- Gram-Positive: Streptococcus pneumoniae, Staphylococcus aureus (MSSA)
- Gram-Negative: Haemophilus influenzae, Escherichia coli, Klebsiella species
- Anaerobes: Bacteroides fragilis, Peptostreptococcus species
- Beta-lactamase Producers: H. influenzae, M. catarrhalis, E. coli
Contraindications:
- Hypersensitivity to penicillins or clavulanic acid
- Previous history of cholestatic jaundice/hepatic dysfunction with amoxicillin/clavulanic acid
- Infectious mononucleosis (risk of skin rash)
Drug Interactions:
- Probenecid: Increases amoxicillin levels
- Warfarin: Monitor INR, may increase bleeding risk
- Methotrexate: Reduced clearance, monitor toxicity
- Oral Contraceptives: May reduce efficacy
Product Specifications
| Product Name |
Semimox-625 |
| Generic Name |
Amoxicillin + Clavulanic Acid |
| Strength |
500mg + 125mg |
| Dosage Form |
Film-coated Tablets |
| Pack Size |
10 x 6 Alu-Alu Blister |
| Therapeutic Class |
Beta-lactam Antibiotic + Beta-lactamase Inhibitor |
| Pharmacological Class |
Penicillin with Enzyme Inhibitor |
| Route of Administration |
Oral |
| Storage Conditions |
Store below 25°C, protect from light and moisture |
| Shelf Life |
24 months from manufacturing date |
| Manufacturer |
MoonSoul Pharmaceuticals Pvt. Ltd. |
| License No. |
MSP/MFG/2024/005 |
| Batch No. |
As per individual pack |
| MRP |
₹197.00 (Inclusive of all taxes) |
| Prescription Status |
Prescription Only Medicine (POM) |
